Introduction
Superior vena caval thrombosis (SVCT) is an uncommon but serious complication of parenteral nutrition with silicone catheters, occurring in 0.2-20% of patients.1-3 Factors known to predispose to the development of SVCT include the composition or incorrect positioning of the catheter and feeding solutions with a high osmolality, especially those in which all the non-protein energy is provided as dextrose.' It has been successfully treated with streptokinase but the risk of haemorrhage and anaphylaxis limit the use of this drug. Recombinant tissue plasminogen (t-PA) activator is an effective fibrinolytic with a lower incidence ofsuch adverse effects. To our knowledge it has not been described in the management of SVCT. This report outlines the use of t-PA in two patients who developed this complication while receiving PN. adhesions following previous surgery for perforated appendicitis and infertility due to pelvic inflammatory disease, but investigation was precluded by the pregnancy. Total parenteral nutrition was commenced to facilitate fetal development prior to delivery and subsequent laparotomy. The nutrient regime is given in the 
Discussion
The development of SVCT is a life-threatening complication, particularly in those patients who are dependent upon parenteral nutrition, which requires rapid effective and safe treatment.
Streptokinase can recanalise the SVC4 but it has certain disadvantages. Repeat usage within three months is contraindicated because of the risk of anaphylaxis.5 It also has the potential for causing serious haemorrhage as it activates the fibrinolytic system throughout the circulation and not just at the site of the thrombus. This is also of importance during pregnancy because bleeding and premature separation of the placenta could occur.
In contrast, t-PA has several advantages as it is the naturally occurring physiological agent that initiates fibrinolysis. Pharmacological preparations are produced by recombinant techniques and therefore anaphylaxis or the production of neutralizing antibodies is unlikely, making repeat usage after recent administration safe and effective. In theory there should be a low risk ofserious bleeding because of the relative selectivity of t-PA for fibrin, and indeed at comparable thrombolytic doses it results in less degradation of fibrinogen than streptokinase.6 However, some clinical trials have reported a similar incidence of significant haemorrhage ofaround 15% although this was with a larger dose of t-PA (150 mg) which has been shown to cause systemic activation of plasmin.7 In addition 80% of the significant bleeding events were associated with coronary bypass surgery or invasive vascular procedures. As both our patients received only 100 mg of t-PA and no invasive procedures were planned the risk of bleeding was considered to be small and justifiable. Furthermore, single chain t-PA has a very short plasma half-life of 5 minutes7 so that if bleeding does occur or if urgent surgical or obstetric intervention is needed then normal haemostasis can rapidly be restored.
The safety of t-PA and streptokinase in human pregnancy has not been established. Neither agent crosses the placenta when administered to pregnant animals but both agents have resulted in fetal death from bleeding or separation of the placenta. However, we considered the short plasma half-life and relative clot selectivity of t-PA to be advantageous.
Neither of our patients suffered any definite side effects although increased platelet aggregation, which has been reported following t-PA, may have contributed to the repeated thrombosis in the first patient.7 It is possible though that this was unrelated as the patient developed recurrent SVCT after streptokinase even before t-PA was given. Furthermore, enhanced platelet aggregation occurs transiently soon after administration of t-PA whereas attenuation ofplatelet aggregation is a more characteristic late phenomenon.7
In conclusion we report the successful use of t-PA in two patients with SVCT and its potential advantages are discussed. 
